LicianPro

AbbVie Inc. ·

ABBV 8-K 2026-10-05

AbbVie Inc. (ABBV) 8-K dated 2026-10-05 — accession 0001551152-26-000030.

AbbVie Inc. (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.

ABBV: SECURITIES AND EXCHANGE COMMISSION

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 8.6% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 49.3.

Not investment advice. The ABBV SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

Guidance
guidance for 2026 previously announced on July 31, 2026 excluded the impact of acquired IPR&D and milestones expense that may be

Why it matters

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr